Program
TQD3524
A development code.
In Sino Biopharmaceutical's pipeline, 多粘菌素E2
. Its studies are mostly in Pneumonia, Bacterial, led by Sino Biopharmaceutical.
Furthest: phase 2, since Mar 27, 20262 company-led studies, 1 open or runningNext primary completion: Jul 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 21 open or running | phase 2since Mar 27, 2026 | Jul 23, 2024 | Jul 2027phase 2 · NCT07512596 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQD3524
, phase 2, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jul 23, 2024First study: phase 1 study in Multi-resistant Gram-negative Bacteria Cause InfectionFirst studyNCT06522945 · 48 enrolled · China
- Mar 27, 2026Phase 2 study in Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial PneumoniaPhase 2 reachedNCT07512596 · 48 planned · China
Ahead
- Jul 2027Primary completion: phase 2 study in Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial PneumoniaNCT07512596
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“多粘菌素E2”the company's pipeline, read by Claude · source
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07512596Hospital-acquired Bacterial Pneumonia/Ventilator-associated Bacterial Pneumonia · China | 2 | Recruiting | Jul 2027 | 48 |
| NCT06522945Multi-resistant Gram-negative Bacteria Cause Infection · China | 1 | Completed | Dec 18, 2025 | 48 |
How it is read
Names in the registry
- “TQD3524”, 7 entries
Codes read as this program: TQD3524.
Conditions, from the studies’ own filings
- Pneumonia, Bacterial, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.